HIV/AIDS Treatment Strategies: Research

For clinical recommendations about combination antiretroviral therapy and other treatments, see Treatment Basics.

For research on individual, FDA-approved antitretroviral drugs, see HIV Medications. For specific HIV drugs in development, see New Drugs.

• Breaking Research From IAS 2009: A Discussion With HIV/AIDS Activists Bob Munk and Matt Sharp (August 26, 2009)
  In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body
  
  
• Researchers Use Sythethic Protein to Block HIV in Laboratory Experiment (August 18, 2009)
  In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• Breaking Research on HIV/AIDS Treatment: An Interview With Joel Gallant, M.D., M.P.H. (August 5, 2009)
  Tune in as Joel Gallant, M.D., M.P.H., one of the United States' foremost HIV experts, walks us through some of the most important findings in HIV treatment strategies presented at the conference.
  In The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
  
  
• Everything Antiretroviral: 5th IAS Conference, Cape Town, South Africa (July 29, 2009)
  A series of brief, down-to-earth summaries of studies on: the "when to start" question; pre-exposure prophylaxis; complications of HAART; aging and HIV; and the latest developments in the search for a cure.
  From Project Inform
  
  
• Key to HIV Eradication May Lie in Memory T Cells, Researchers Say (June 24, 2009)
  From The Body
  
  
• Herpes Drug Acyclovir Does Not Reduce Risk of HIV Transmission, Does Slow HIV Progression, Study Says (May 14, 2009)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• A Cheaper, Safer Sustiva? Gates Foundation to Fund Trials of Lower HIV Drug Doses (April 29, 2009)
  From aidsmap.com
  
  
• HIV Might Be Becoming Increasingly Virulent, Study Says (April 17, 2009)
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• A, B, C, D: Regardless of Your HIV Subtype, HIV Meds Work Well, Study Says (April 15, 2009)
  From aidsmap.com
  
  
• Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment (April 14, 2009)
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Drug Watch: Nanotechnology for Antiretroviral Delivery (Winter/Spring 2009)
  To read PDF, click here
  In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
  
  
• An Update on the Present -- and Future -- of HIV Eradication (February 8, 2009)
  Robert Siliciano, M.D., is one of the world's foremost researchers on the topic of HIV eradication. We caught up with him at CROI 2009 to discuss recent developments in the field, which has suddenly experienced somewhat of a renaissance of late.
  In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• The Next Stage of HIV Eradication: Finding the Secret Reservoirs (February 8, 2009)
  In adherent patients on fully suppressive HAART, viral replication has completely stopped, says Robert Siliciano, M.D., Ph.D. But the virus still lurks persistently in reservoirs -- one whose identity is known, and at least one whose identity remains a mystery.
  In 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Immune System Defects Persist in People Who Start Treatment Late (January 13, 2009)
  From aidsmap.com
  
  
• Monitoring Board Recommends Stopping Experimental Treatment Regimen in International Study of Patients New to HIV Treatment (May 27, 2008)
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• Once-a-Month HIV Therapy: Could Nanotechnology Be the Next Treatment Frontier? (April 2008)
  A simple explanation of new research on the use of nanotechnology in HIV treatment.
  To read PDF, click here
  In Project Inform Perspective, from Project Inform
  
  
• HIV Gene Therapy 'Shows Promise' (November 6, 2006)
  From BBC News
  
  
• Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
  [Archived Article]
  In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
  In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
  
  
• Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
  [Archived Article]
  A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
  From The Body PRO
  
  
• Viral Load Between 400 and 20,000 Can Still Maintain Patient Health (September 7, 2004)
  [Archived Article]
  Partially suppressive HAART appears to protect against death and illness as well as fully suppressive HAART.
  From aidsmap.com
  
  
• CD4-Guided Pulse Therapy; Induction/Maintenance Therapy: Research From AIDS 2004 (September 2004)
  [Archived Article]
  A list of studies examining these two therapy-sparing approaches to HIV treatment.
  In TAGline, from Treatment Action Group
  
  
• Genetics Influence Response to HAART and Incidence of Pancreatitis, Studies Show (August 3, 2004)
  [Archived Article]
  From aidsmap.com
  
  
• French Researchers Question Benefit of Lifelong Antiretroviral Treatment (August 2004)
  [Archived Article]
  A small, limited study suggests that after three years of use, HAART may reach the apex of its immunologic benefit.
  In TAGline, from Treatment Action Group
  
  
• Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
  [Archived Article]
  In The XV International AIDS Conference, from The Body PRO
  
  
• Most Common HAART Regimens Yield Equal Chances of Survival, San Francisco Study Finds (July 12, 2004)
  [Archived Article]
  In The XV International AIDS Conference, from The Body PRO
  
  
• Risk Factors Associated With Delayed Entry to Care (July 12, 2004)
  [Archived Article]
  In The XV International AIDS Conference, from The Body PRO
  
  
• Gender, Youth, Race/Ethnicity, Treatment Interruption Tied to Risk for Virologic Failure (February 9, 2004)
  [Archived Article]
  In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Clinical Efficacy of Antiretroviral Combination Therapy Based on Protease Inhibitors or Non-Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials (January 31, 2004)
  [Archived Article]
  Three-drug regimens containing a protease inhibitor are found to more effectively suppress HIV than three-drug regimens containing NNRTIs.
  In British Medical Journal
  
  
• Wait Six Months After HIV Treatment Begins to Determine Prognosis, Study Says (August 29, 2003)
  [Archived Article]
  In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
  
  
• Low-Level Viremia: Smoke or Fire? (April 2003)
  [Archived Article]
  A summary of study results from CROI 2003.
  In IAPAC Monthly, from International Association of Physicians in AIDS Care
  
  
• No Care Equals Bad Care: A Talk With Sam Bozzette, M.D., Ph.D. (April 2003)
  [Archived Article]
  An analysis of what the future holds for patient-centered care.
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Key Therapeutic Decisions in Managing HIV Infection (Spring 2003)
  [Archived Article]
  An update on when to start, when to switch and when to stop, from STEP's conference review of Retrovirus 2003.
  In STEP Perspective, from Seattle Treatment Education Project
  
  
• Top Papers of 2002 (January 2003)
  [Archived Article]
  Brief summaries of the 12 most important HIV-related publications of last year, compiled by HIV researcher Dr. John G. Bartlett.
  In Hopkins HIV Report
  
  
• What to Start With and What to Include? Should Compounds With Non Cross-Resistance Profiles Be Preferentially Used in Initial or Late Therapy? (November 18, 2002)
  [Archived Article]
  In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
  
  
• Antiviral Therapy 2002 (November 17, 2002)
  [Archived Article]
  In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
  
  
• Genotyping Less Effective at Predicting Effective Regimens in Children (October 4, 2002)
  [Archived Article]
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• T-20 May Help Expand Number of Treatable Groups (September 30, 2002)
  [Archived Article]
  In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
  
  
• Clinical Pathway Lectures (August 2002)
  [Archived Article]
  Part of the 2002 Ryan White CARE Act Grantee Meeting in August, the Clinical Pathway online lectures focus on current clinical issues in HIV management.
  From International AIDS Society-USA
  
  
• Selected Highlights From Retrovirus: New Anti-HIV Medications (February 28, 2002)
  [Archived Article]
  In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) Regimens in Combination With Efavirenz (EFV) in Healthy Adult Subjects (APV10010) (February 27, 2002)
  [Archived Article]
  In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Identification and Characterization of a Novel Inhibitor of HIV-1 Entry (February 25, 2002)
  [Archived Article]
  In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Immune Reconstitution and Immunologic Responses to Antiretroviral Therapies: Implications for Therapeutic Strategies (February 25, 2002)
  [Archived Article]
  In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy (January 28, 2002)
  [Archived Article]
  Results from the EuroSIDA Study.
  In Journal of Infectious Diseases
  
  
• An Assessment of Plasma Amprenavir (APV) Pharmacokinetics (PK) Following Administration of Two GW433908 (908) and Ritonavir (RTV) QD Regimens in Combination with Efavirenz (EFV) in Healthy Adult Subjects (APV10009) (December 18, 2001)
  [Archived Article]
  In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
  
  
• A Phase IV Randomized Open-Label Multicenter Trial to Evaluate Safety and Efficacy of Indinavir/Ritonavir (800/100 mg BID) vs. Saquinavir/Ritonavir (1,000/100 mg BID) in Adult HIV-1 Infection: The Max Cmin 1 Trial (October 29, 2001)
  [Archived Article]
  In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
  
  
• HAART and the Management of HIV-1 Infection: Can Short-Term Changes in the Plasma HIV-1 RNA Level Predict Long-Term Response to Therapy? (October 27, 2001)
  [Archived Article]
  In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
  
  
• The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
  [Archived Article]
  In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
  
  
• The Road to Eradication: Is HAART Hard Enough? (October 27, 2001)
  [Archived Article]
  In The PRN Notebook
  
  
• Short-Term Immuno-Suppressive Therapy With Prednisolone in HIV-1-Infected Patients Receiving Abacavir With or Without Nevirapine (July 10, 2001)
  [Archived Article]
  In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
  
  
• Evaluation of the Anti-HIV-1 Potency of Several Nucleoside RT Inhibitors in PBL, Macrophages, and MT4 Cells, In Vitro (July 9, 2001)
  [Archived Article]
  In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
  
  
• Current Controversies in Antiretroviral Therapy and Potential Solutions: Translating Science into Action (July 8, 2001)
  [Archived Article]
  In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
  
  
• Using Multiple Drugs in Combination Helps Patients With Advanced AIDS (July 3, 2001)
  [Archived Article]
  In Annals of Internal Medicine
  
  
• AIDS Drug Combo Fares Well in Study (July 2001)
  [Archived Article]
  In Body Positive, from Body Positive
  
  
• Optimizing Available Antiretroviral Therapies (February 8, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• The CSF Concentration/IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (February 7, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Antiretroviral Intensification Accelerates the Decay of the Latent Reservoir of HIV-1 and Decreases but Does Not Eliminate Ongoing Virus Replication (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Continued Low Mortality and Morbidity, and HAART Utilization among HIV-Infected Patients in the HIV Outpatient Study (HOPS) (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Effectiveness of Antiretroviral Therapy in the Elderly Compared to a Younger Cohort (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Long-Term Survival After Initiation of Antiretroviral Therapy (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (ddI), Tenofovir (TFV), and the Combination of ABC and ddI In Vitro (February 6, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Antiretroviral Therapy (ART) Plus Cyclophosphamide (CTX) to Diminish HIV DNA in Lymphoid Tissue (February 5, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
  [Archived Article]
  In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Pendulum Swing (January 2001)
  [Archived Article]
  An interview with doctors and nurses at St. Vincent's Hospital in New York about current HIV treatment practices.
  In TAGline, from Treatment Action Group
  
  
• Anti-HIV Drugs Update (October 2000)
  [Archived Article]
  In Project Inform Perspective, from Project Inform
  
  
• Anti-HIV Drug Update (August 2000)
  [Archived Article]
  Recent studies of dual protease inhibitor combinations, and protease inhibitor/NNRTI combinations and dual NNRTI combinations.
  In Project Inform Perspective, from Project Inform
  
  
• Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
  [Archived Article]
  In The XIII International AIDS Conference, from The Body PRO
  
  
• Full Plasma Viral Load Suppression is Needed to Achieve an Optimal CD4 Response Among Patients Receiving Triple-drug Antiretroviral Therapy (July 12, 2000)
  [Archived Article]
  In The XIII International AIDS Conference, from The Body PRO
  
  
• Studies Suggest AZT/3TC/Abacavir May Offer Adequate Potency (July 12, 2000)
  [Archived Article]
  In The XIII International AIDS Conference, from The Body PRO
  
  
• Animal Models -- Interventions (July 10, 2000)
  [Archived Article]
  In The XIII International AIDS Conference, from The Body PRO
  
  
• Symposium: The Science of HIV/AIDS: Evolution & Impact (July 10, 2000)
  [Archived Article]
  In The XIII International AIDS Conference, from The Body PRO
  
  
• ART Real World: Observational Databases Promise to Solve Clinical Trials Lag, but Experts Warn All Data Not Created Equal (March 2000)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• Behemoth: Eradication's Ebb Finds Researchers Wrestling Again With Clinical Outcome Concerns (March 2000)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• HIV Persists Despite HAART (Spring 2000)
  [Archived Article]
  In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
  
  
• HIV Watch: Understanding Immune Recovery (February 2000)
  [Archived Article]
  In Positive Living, from AIDS Project Los Angeles
  
  
• Immunogenicity of Revaccination with Pneumococcal Vaccine in HIV-Infected Patients on Combination Antiretroviral Therapy (January 31, 2000)
  [Archived Article]
  In The 7th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• When Should PIs Be Used? (November 1999)
  [Archived Article]
  Wisdom or folly of sparing protease inhibitors explored at ICAAC.
  In Positive Living, from AIDS Project Los Angeles
  
  
• Rapid Rebound of HIV and Reappearance of HIV Reservoirs in Patients Treated with IL-2 and Combination Antiretroviral Drugs Following Cessation of Therapy (October 27, 1999)
  [Archived Article]
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• New Model Suggests that AIDS Drugs May Not Abolish HIV Infection (October 6, 1999)
  [Archived Article]
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• Advances in Research: Second & Third Line Therapy (September 1999)
  [Archived Article]
  In Project Inform Perspective, from Project Inform
  
  
• Fall of HAART (September/October 1999)
  [Archived Article]
  Leading stories from the fall's major medical meetings.
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Going Wild (Type) with Structured Treatment Interruptions (STIs) (September/October 1999)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Mycophenylate -- A Potential New Option (September 1999)
  [Archived Article]
  In Project Inform Perspective, from Project Inform
  
  
• Community Alert: Experimental Drug Combinations (August 1999)
  [Archived Article]
  From Project Inform
  
  
• Community Alert: Experimental Drug Dosing Schemes with Protease Inhibitors (August 1999)
  [Archived Article]
  From Project Inform
  
  
• From the Editor (July 1999)
  [Archived Article]
  Death Takes a Holiday and the current state of HIV disease management.
  In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
  
  
• Maintenance Therapy for HIV (June 1999)
  [Archived Article]
  In Body Positive, from Body Positive
  
  
• A Three-Drug Combination is the Minimum Standard of Care (Spring 1999)
  [Archived Article]
  In Women Alive Newsletter, from Women Alive
  
  
• Continual Suppression to Yield to Pulsed Therapy? (March, 1999)
  [Archived Article]
  From Treatment Action Group
  
  
• Strategy Trials: The Answer? (February 18, 1999)
  [Archived Article]
  From AIDS Treatment News
  
  
• HIV-Specific Immunity: Major Conference Sessions (February 12, 1999)
  [Archived Article]
  From AIDS Treatment News
  
  
• Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 9, 1999)
  [Archived Article]
  Summary by Donald L. Kaminsky, M.D.
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Phase III, Multicenter, Randomized, Open-Label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz (EFV) + Indinavir (IDV), versus EFV + Zidovudine (ZDV) + Lamuvidine (3TC), versus IDV + ZDV + 3TC at 48 Weeks (Study DMP 266-006) (February 4, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• ACTG 364: Virologic Efficacy of Nelfinavir (NFV) and/or Efavirenz (EFZ) in Combination with New Nucleoside Analogs in Nucleoside Experienced Subjects (February 3, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• The Long Term Response to Combination Therapy Commenced Early in HIV Infection: 3 Year Follow-Up: What's Happened Since Vancouver? (February 3, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Co-Administration of Indinavir 1200 mg with Nelfinavir 1250 mg in a Twice Daily Regimen: Preliminary Safety, PK Activity (February 2, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Phase I/II Dosing Study of Once-Daily Hydroxyurea Alone vs Didanosine Alone vs ddI + HU (February 2, 1999)
  [Archived Article]
  Summary by Kent Sepkowitz, M.D.
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Viral Fitness in Patients with Discordant CD4 and Plasma HIV RNA following Protease Inhibitor Failure (February 2, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Mutations in the Reverse Transcriptase Genome of HIV I Isolates Derived from Subjects Treated with Didanosine and Stavudine in Combination (February 1, 1999)
  [Archived Article]
  In The 6th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Trials & Errors: Studies Look at Which Combinations Are Better (February 1999)
  [Archived Article]
  Clinical trials using NNRTIs with or instead of protease inhibitors.
  From Seattle Treatment Education Project
  
  
• 1999: Treatments, Issues to Watch (January 8, 1999)
  [Archived Article]
  From AIDS Treatment News
  
  
• Robert Gallo Calls for New Treatment Approach (January 8, 1999)
  [Archived Article]
  From AIDS Treatment News
  
  
• If Silence = Death, Will Numbers = Answers? (December 1998)
  [Archived Article]
  In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
  
  
• Treatment with IL-2 Plus HAART Markedly Reduces HIV in Immune System "Hiding Places" (November 15, 1998)
  [Archived Article]
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• Studies End Hopes of Reducing Complex Regimen of AIDS Drugs (November 7, 1998)
  [Archived Article]
  By Scott Gottlieb.
  In British Medical Journal
  
  
• Effectiveness of Potent Antiretroviral Therapy on Time to AIDS and Death in Men With Known HIV Infection Duration (November 4, 1998)
  [Archived Article]
  The results of The Multicenter AIDS Cohort Study.
  In Journal of the American Medical Association
  
  
• Antiviral Therapy: How Simple Can You Get? (November 1998)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Five-drug regimen produces sharp reductions in viral load (October, 1998)
  [Archived Article]
  In HIV Newsline, from San Francisco General Hospital
  
  
• Simultaneous initiation of three-drug regimen more effective than adding drugs sequentially (October, 1998)
  [Archived Article]
  In HIV Newsline, from San Francisco General Hospital
  
  
• The CHORUS Database on Patient Clinical Care -- and Interview with Stephen Becker, M.D. (August 21, 1998)
  [Archived Article]
  From AIDS Treatment News
  
  
• Antiviral Effect of AZT versus D4T in Combination with 3TC and Indinavir in the Context of a Population-Based Study (July 2, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Co-Administration of Indinavir 1000mg and Escalating Nelfinavir Dose in a Twice-Daily Regimen: Preliminary Safety, Pharmacokinetic and Antiviral Activity (June 30, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Combining Indinavir with Ritonavir (June 30, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Pharmacokinetic Interaction Between Nevirapine and Indinavir and Correlation with Antiviral Activity (June 30, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Does Sequential Therapy Offer Any Advantage Over Continuous Therapy? (June 29, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Sixteen-Week Followup of Indinavir Sulfate (Crixivan) Administered Every 8 Hours versus Every 12 Hours in Combination with Efavirenz (June 29, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Summaries of Four Recent Combination Therapy Studies (June 29, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• What's the Latest in the Induction/Maintenance Approach to Therapy? (June 29, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Simultaneous vs. Sequential Initiation of Therapy with Indinavir (Crixivan), Zidovudine (AZT) and Lamuvidine (3TC) for HIV Infection: 100 Week Follow-Up (June 27, 1998)
  [Archived Article]
  In The 12th International AIDS Conference, from The Body PRO
  
  
• Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance (June 24, 1998)
  [Archived Article]
  In Journal of the American Medical Association
  
  
• More News from the 5th Conference on Retroviruses and Opportunistic Infections (April 1998)
  [Archived Article]
  Coverage of research on new combination therapies.
  In HIV Newsline, from San Francisco General Hospital
  
  
• U.S. and French Investigators Alike Are 'Shocked, shocked' to Learn of Maintenance Protocol's Failure (April 1998)
  [Archived Article]
  From Treatment Action Group
  
  
• Moods Brighten as Statistics Lighten (March 1998)
  [Archived Article]
  Highlights of research reports, from the 5th Conference on Retroviruses and Opportunistic Infections.
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Clinical Implications of Virological "Failure" (February 20, 1998)
  [Archived Article]
  Interview with Steven Deeks, M.D., San Francisco General Hospital.
  In AIDS Treatment News, from AIDS Treatment News
  
  
• A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
  [Archived Article]
  From Seattle Treatment Education Project
  
  
• Efavirenz + Indinavir (February 4, 1998)
  [Archived Article]
  In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
  [Archived Article]
  In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
  [Archived Article]
  In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm³ (February 3, 1998)
  [Archived Article]
  In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
  [Archived Article]
  In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• 2, 4, 6, 8, Who's Afraid to Phosphorylate? (February 1998)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• The Next Generation of Antiretroviral Agents (February 1998)
  [Archived Article]
  In AIDS Care, from San Francisco General Hospital
  
  
• Antimicrobial Agents and Chemotherapy (December 1997)
  [Archived Article]
  A survey of new approaches in antiretroviral therapy from ICAAC '97.
  In Body Positive, from Body Positive
  
  
• Drug-Drug Interactions: An Update (December 1997)
  [Archived Article]
  In HIV Newsline, from San Francisco General Hospital
  
  
• The Next Generation of Antiretroviral Agents -- An Update (December 1997)
  [Archived Article]
  In HIV Newsline, from San Francisco General Hospital
  
  
• Treatment Issues' Second Survey of Physicians' Treatment Practice (December 1997/January 1998)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Sometimes Less is More (November 1997)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Delavirdine Combination and Viral Load (October 17, 1997)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Combination Therapy for HIV Infection: Why to Use More Than One Drug, and Which Drugs to Use (October 1997)
  [Archived Article]
  In IAPAC Monthly, from International Association of Physicians in AIDS Care
  
  
• HIV Late Breakers I (September 28-October 1, 1997)
  [Archived Article]
  In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
  
  
• Impact of Highly Active Antiretroviral Therapy on Opportunistic Infections (3 abstracts) (September 28-October 1, 1997)
  [Archived Article]
  In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
  
  
• Low Key Dual Combo Appears First to Achieve the Unimaginable (October, 1997)
  [Archived Article]
  From Treatment Action Group
  
  
• Saquinavir Soft Gel Capsules Versus Indinavir as Part of AZT and 3TC Containing Triple Therapy (September 28-October 1, 1997)
  [Archived Article]
  In The 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
  
  
• Engineered Virus Targets HIV-Infected Cells: Interview with Garry Nolan, Ph.D. (September 19, 1997)
  [Archived Article]
  From AIDS Treatment News
  
  
• "Trojan Horse" Virus Controls HIV Infection (September 1997)
  [Archived Article]
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• Antioxidants May Still Have a Role in HIV Treatment (September 1997)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• ACTG 300 Leaves Many Questions Unanswered (July/August 1997)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Limited Immune Recovery After Treatment with Antiretrovirals, IL-2: Interview with Clifford Lane, M.D. (June 1997)
  [Archived Article]
  From AIDS Treatment News
  
  
• Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke (April 1997)
  [Archived Article]
  From Treatment Action Group
  
  
• The Need for 'Strategy' Type Clinical Studies (March 1997)
  [Archived Article]
  From Treatment Action Group
  
  
• Staring into the Precipice: Resistance and Cross-Resistance Among Protease Inhibitors (February 7, 1997)
  [Archived Article]
  From Treatment Action Group
  
  
• Antiretroviral Drug Interaction Studies Show Favorable Effects (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• AZT Resistance Predicts Poor Outcome (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• ddI + d4T Combination Therapy Proves Effective (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Protease Combinations May Be the Most Effective (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• Triple Combination Therapy Including Indinavir Is Effective in Advanced AIDS (January 1997)
  [Archived Article]
  In The 4th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
  
  
• d4T+AZT -- Unexpected CD4 Drop Seen in Study (December 20, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Europeans Eye New Drug Cocktails (December 1996)
  [Archived Article]
  Third International Conference on Drug Therapy in HIV Infection.
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Nevirapine's Effect on Indinavir Levels (December 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Large Combination Trials with AZT, ddI, ddC: Results Published (October 18, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Anti-HIV Agents at ICAAC (October 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Early Treatment Choices and Their Unintended Consequences (Hitting it Early, Hard) (October 1996)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• TAG interviews Dr. David Ho on the effect of the new antiretroviral combinations over time (October, 1996)
  [Archived Article]
  From Treatment Action Group
  
  
• When Highly Active Antiretroviral Therapy (HAART) is Not Enough (October, 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• ddI plus d4T (September 6, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Antiretroviral Therapy (September 1996)
  [Archived Article]
  In Hopkins HIV Report, from Johns Hopkins AIDS Service
  
  
• Can HIV Be Cured? (September 1996)
  [Archived Article]
  In Hopkins HIV Report, from Johns Hopkins AIDS Service
  
  
• Delavirdine/Protease Inhibitor Interactions (September 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Snapshots of the Literature (September 1996)
  [Archived Article]
  In Hopkins HIV Report, from Johns Hopkins AIDS Service
  
  
• Aaron Diamond's Dynamic Duo: The Latest Word on Protease Resistance (August/September 1996)
  [Archived Article]
  Treatment Activists Sit Down with Vancouver High Fliers, Try to Make Sense Out of the New Cries of 'Eureka' .
  In TAGline, from Treatment Action Group
  
  
• AZT/3TC Clinical Endpoint Analyses (August 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Data from Protease Inhibitor Combination Trials Shows Sustained Benefit (August 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• More Information on Hydroxyurea (August 1996)
  [Archived Article]
  In combination with ddI.
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Expert Panel's New Recommendations for Antiviral Treatment (July 19, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• New View of Antiretroviral Treatment: Illustrations from "Late Breaker" Abstracts (July 19, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Snapshots of the Literature (July 1996)
  [Archived Article]
  In Hopkins HIV Report, from Johns Hopkins AIDS Service
  
  
• Clinically Clueless: Keystone Group Addresses Crisis in Post-Marketing Treatment Research and Access to FDA-Approved Therapies (June 1996)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• Immunologic Factors & Therapy (report from the XIth International AIDS Conference) (Summer 1996)
  [Archived Article]
  In STEP Perspective, from Seattle Treatment Education Project
  
  
• Throw Down Your Crutches and Walk (June/July 1996)
  [Archived Article]
  In GMHC Treatment Issues, from Gay Men's Health Crisis
  
  
• Viral Eradication (report from the XIth International AIDS Conference) (Summer 1996)
  [Archived Article]
  In STEP Perspective, from Seattle Treatment Education Project
  
  
• Comparing the (RTI) Combinations: Reported maximum average reductions in plasma HIV RNA with selected RTI combination regimens (in treatment naive individuals) (April 1996)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• Snapshots of the Literature (March 1996)
  [Archived Article]
  In Moore News for Care Providers, from Johns Hopkins AIDS Service
  
  
• Study Finds AIDS Patients Live Longer When Their Doctors Have More Experience Treating HIV (March 1, 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• d4T Plus ddI Antiviral Results (February 1996)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Lamivudine Approved for Combination Use with AZT (December 1, 1995)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• San Francisco Area: Testosterone Replacement Study, Injection vs. Patch (October 20, 1995)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• AZT Delta Study: Major European/Australian Study Finds Combinations Better Than AZT Alone (October 6, 1995)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Community Envoy to Food and Drug Panel Urges Caution in Approving New Anti-HIV Therapueutics and in Providing Early Access (October, 1995)
  [Archived Article]
  An excerpt from Peter Staley's remarks to the FDA's advisory committee regarding its Accelerated Approval program and viral load tests.
  In TAGline, from Treatment Action Group
  
  
• Nucleoside Analogue Drug Combinations (October, 1995)
  [Archived Article]
  From amfAR, The Foundation for AIDS Research
  
  
• ACTG 175: Anti-HIV Therapy Lowers Risk of AIDS, Death in Patients with Intermediate-Stage HIV Disease (September 1995)
  [Archived Article]
  From U.S. National Institute of Allergy and Infectious Diseases
  
  
• New Antiretroviral Strategies: Interview with Marcus Conant, M.D. (August 4, 1995)
  [Archived Article]
  In AIDS Treatment News, from AIDS Treatment News
  
  
• Report on Drug Development from the HIV Immune-based Therapies Workshop (March 1995)
  [Archived Article]
  In TAGline, from Treatment Action Group
  
  
• The Intra-Company Cooperative Triple Drug Combination (June 1994)
  [Archived Article]
  In TAGline, from Treatment Action Group